Global Biologics Contract Manufacturing Market Research Report

 The findings reviewed by GME stated that the Global Biologics Contract Manufacturing Market will expand with a CAGR value 8.2%. Increasing incidences of cancer and other chronic diseases have increased the demand for pharmaceutical drugs in the market. Increased production costs due to government regulations on clinical trials and other costs have resulted in pharmaceutical companies outsourcing production from development stages to drug dose selection to manufacturing to packaging.

Browse 159 Market Data Tables and 119 Figures spread through 189 Pages and in-depth TOC on "Biologics Contract Manufacturing Market - Forecast to 2026" 

https://www.globalmarketestimates.com/market-report/global-biologics-contract-manufacturing-market-2773

By Product (Monoclonal Antibodies, Vaccines, Growth Factors, Interferons, Recombinant Hormones, Insulin, Others), By Platform (Mammalian, Microbial), By Application (Clinical, Commercial),By Region (North America, Asia Pacific, CSA, Europe, and the Middle East and Africa); End-User Landscape, Company Market Share Analysis & Competitor Analysis

 Key Market Insights

·         Biologics are bioengineered protein-based drugs that are sourced from organic materials like mammalian and microbial sources.

·         The pharmaceutical companies outsource drug production to biologic contract manufacturing vendors due to increasing drug production cost.

·         In terms of market value or revenue, the largest shareholder as per platform outlook was the microbial segment in 2020.

·         Lonza Group, BioXcellence, AG Samsung Biologics Co. Ltd., AbbVie Contract Manufacturing, Fujifilm Diosynth Biotechnologies (FUJIFILM Holdings), WuXi Biologics Inc., AGC Biologics, Ajinomoto Bio-Pharma, Patheon N.V., Emergent BioSolutions Inc., Avid Bioservices Inc., Catalent Inc., KBI Biopharma, and Abzena Plc, among others, are the major vendors competing in the biologics contract manufacturing market.

 

Browse the Report @ https://www.globalmarketestimates.com/market-report/global-biologics-contract-manufacturing-market-2773

Product Outlook (Revenue, USD Billion, 2021-2026)

·         Monoclonal Antibodies

·         Vaccines

·         Growth Factors

·         Interferons

·         Recombinant Hormones

·         Insulin

·         Others

Platform Outlook (Revenue, USD Billion, 2021-2026)

·         Mammalian

·         Microbial

Application Outlook (Revenue, USD Billion, 2021-2026)

·         Clinical

·         Commercial

Regional Outlook (Revenue, USD Billion, 2021-2026)

North America                                                                                 

• The U.S.
• Canada
• Mexico

Europe

• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe

 

Asia Pacific

• China
• India
• Japan
• South Korea
• Australia
• Rest of APAC

Central & South America

• Brazil
• Argentina
• Rest of CSA

Middle East & Africa

• Saudi Arabia
• UAE
• Rest of MEA

 

Contact: Tracy Simon

Email address: tracy.simon@globalmarketestimates.com

Phone Number: +16026667238

Website: Global Market Estimates